TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes

Sung W. Choi, Patrick Stiff, Kenneth R Cooke, James L M Ferrara, Thomas Braun, Carrie Kitko, Pavan Reddy, Gregory Yanik, Shin Mineishi, Sophie Paczesny, David Hanauer, Attaphol Pawarode, Edward Peres, Tulio Rodrigue, Scott Smith, John E. Levine

Research output: Contribution to journalArticle

Abstract

Graft-versus-host disease (GVHD) causes most non-relapse mortality (NRM) after alternative donor (unrelated and mismatched related) hematopoietic cell transplant (HCT). We previously showed that increases in day +7 TNF-receptor-1 (TNFR1) ratios (posttransplantation day +7/pretransplantation baseline) after myeloablative HCT correlate with outcomes including GVHD, NRM, and survival. Therefore, we conducted a phase II trial at 2 centers, testing whether the addition of the TNF-inhibitor etanercept (25 mg twice weekly from start of conditioning to day +56) to standard GVHD prophylaxis would lower TNFR1 levels, reduce GVHD rates, and improve NRM and survival. Patients underwent myeloablative HCT from a matched unrelated donor (URD; N = 71), 1-antigen mismatched URD (N = 26), or 1-antigen mismatched related donor (N = 3) using either total body irradiation (TBI)-based conditioning (N = 29) or non-TBI-based conditioning (N = 71). Compared to historical controls, the increase in posttransplantation day +7 TNFR1 ratios was not altered in patients who received TBI-based conditioning, but was 40% lower in patients receiving non-TBI-based conditioning. The latter group experienced relatively low rates of severe grade 3 to 4 GVHD (14%), 1-year NRM (16%), and high 1-year survival (69%). These findings suggest that (1) the effectiveness of TNF-inhibition with etanercept may depend on the conditioning regimen, and (2) attenuating the expected rise in TNFR1 levels early posttransplantation correlates with good outcomes.

Original languageEnglish (US)
Pages (from-to)1525-1532
Number of pages8
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume18
Issue number10
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Tumor Necrosis Factor Receptors
Graft vs Host Disease
Transplants
Unrelated Donors
Mortality
Whole-Body Irradiation
Survival
Antigens
Etanercept
Tissue Donors

Keywords

  • GVHD
  • Hematopoietic cell transplantation
  • TNF-α
  • TNFR1

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT : Lower TNFR1 Levels Correlate with Better Outcomes. / Choi, Sung W.; Stiff, Patrick; Cooke, Kenneth R; Ferrara, James L M; Braun, Thomas; Kitko, Carrie; Reddy, Pavan; Yanik, Gregory; Mineishi, Shin; Paczesny, Sophie; Hanauer, David; Pawarode, Attaphol; Peres, Edward; Rodrigue, Tulio; Smith, Scott; Levine, John E.

In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, Vol. 18, No. 10, 10.2012, p. 1525-1532.

Research output: Contribution to journalArticle

Choi, SW, Stiff, P, Cooke, KR, Ferrara, JLM, Braun, T, Kitko, C, Reddy, P, Yanik, G, Mineishi, S, Paczesny, S, Hanauer, D, Pawarode, A, Peres, E, Rodrigue, T, Smith, S & Levine, JE 2012, 'TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes', Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol. 18, no. 10, pp. 1525-1532. https://doi.org/10.1016/j.bbmt.2012.03.013
Choi, Sung W. ; Stiff, Patrick ; Cooke, Kenneth R ; Ferrara, James L M ; Braun, Thomas ; Kitko, Carrie ; Reddy, Pavan ; Yanik, Gregory ; Mineishi, Shin ; Paczesny, Sophie ; Hanauer, David ; Pawarode, Attaphol ; Peres, Edward ; Rodrigue, Tulio ; Smith, Scott ; Levine, John E. / TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT : Lower TNFR1 Levels Correlate with Better Outcomes. In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 10. pp. 1525-1532.
@article{2a514953fb094cf1889627530e5d7708,
title = "TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes",
abstract = "Graft-versus-host disease (GVHD) causes most non-relapse mortality (NRM) after alternative donor (unrelated and mismatched related) hematopoietic cell transplant (HCT). We previously showed that increases in day +7 TNF-receptor-1 (TNFR1) ratios (posttransplantation day +7/pretransplantation baseline) after myeloablative HCT correlate with outcomes including GVHD, NRM, and survival. Therefore, we conducted a phase II trial at 2 centers, testing whether the addition of the TNF-inhibitor etanercept (25 mg twice weekly from start of conditioning to day +56) to standard GVHD prophylaxis would lower TNFR1 levels, reduce GVHD rates, and improve NRM and survival. Patients underwent myeloablative HCT from a matched unrelated donor (URD; N = 71), 1-antigen mismatched URD (N = 26), or 1-antigen mismatched related donor (N = 3) using either total body irradiation (TBI)-based conditioning (N = 29) or non-TBI-based conditioning (N = 71). Compared to historical controls, the increase in posttransplantation day +7 TNFR1 ratios was not altered in patients who received TBI-based conditioning, but was 40{\%} lower in patients receiving non-TBI-based conditioning. The latter group experienced relatively low rates of severe grade 3 to 4 GVHD (14{\%}), 1-year NRM (16{\%}), and high 1-year survival (69{\%}). These findings suggest that (1) the effectiveness of TNF-inhibition with etanercept may depend on the conditioning regimen, and (2) attenuating the expected rise in TNFR1 levels early posttransplantation correlates with good outcomes.",
keywords = "GVHD, Hematopoietic cell transplantation, TNF-α, TNFR1",
author = "Choi, {Sung W.} and Patrick Stiff and Cooke, {Kenneth R} and Ferrara, {James L M} and Thomas Braun and Carrie Kitko and Pavan Reddy and Gregory Yanik and Shin Mineishi and Sophie Paczesny and David Hanauer and Attaphol Pawarode and Edward Peres and Tulio Rodrigue and Scott Smith and Levine, {John E.}",
year = "2012",
month = "10",
doi = "10.1016/j.bbmt.2012.03.013",
language = "English (US)",
volume = "18",
pages = "1525--1532",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT

T2 - Lower TNFR1 Levels Correlate with Better Outcomes

AU - Choi, Sung W.

AU - Stiff, Patrick

AU - Cooke, Kenneth R

AU - Ferrara, James L M

AU - Braun, Thomas

AU - Kitko, Carrie

AU - Reddy, Pavan

AU - Yanik, Gregory

AU - Mineishi, Shin

AU - Paczesny, Sophie

AU - Hanauer, David

AU - Pawarode, Attaphol

AU - Peres, Edward

AU - Rodrigue, Tulio

AU - Smith, Scott

AU - Levine, John E.

PY - 2012/10

Y1 - 2012/10

N2 - Graft-versus-host disease (GVHD) causes most non-relapse mortality (NRM) after alternative donor (unrelated and mismatched related) hematopoietic cell transplant (HCT). We previously showed that increases in day +7 TNF-receptor-1 (TNFR1) ratios (posttransplantation day +7/pretransplantation baseline) after myeloablative HCT correlate with outcomes including GVHD, NRM, and survival. Therefore, we conducted a phase II trial at 2 centers, testing whether the addition of the TNF-inhibitor etanercept (25 mg twice weekly from start of conditioning to day +56) to standard GVHD prophylaxis would lower TNFR1 levels, reduce GVHD rates, and improve NRM and survival. Patients underwent myeloablative HCT from a matched unrelated donor (URD; N = 71), 1-antigen mismatched URD (N = 26), or 1-antigen mismatched related donor (N = 3) using either total body irradiation (TBI)-based conditioning (N = 29) or non-TBI-based conditioning (N = 71). Compared to historical controls, the increase in posttransplantation day +7 TNFR1 ratios was not altered in patients who received TBI-based conditioning, but was 40% lower in patients receiving non-TBI-based conditioning. The latter group experienced relatively low rates of severe grade 3 to 4 GVHD (14%), 1-year NRM (16%), and high 1-year survival (69%). These findings suggest that (1) the effectiveness of TNF-inhibition with etanercept may depend on the conditioning regimen, and (2) attenuating the expected rise in TNFR1 levels early posttransplantation correlates with good outcomes.

AB - Graft-versus-host disease (GVHD) causes most non-relapse mortality (NRM) after alternative donor (unrelated and mismatched related) hematopoietic cell transplant (HCT). We previously showed that increases in day +7 TNF-receptor-1 (TNFR1) ratios (posttransplantation day +7/pretransplantation baseline) after myeloablative HCT correlate with outcomes including GVHD, NRM, and survival. Therefore, we conducted a phase II trial at 2 centers, testing whether the addition of the TNF-inhibitor etanercept (25 mg twice weekly from start of conditioning to day +56) to standard GVHD prophylaxis would lower TNFR1 levels, reduce GVHD rates, and improve NRM and survival. Patients underwent myeloablative HCT from a matched unrelated donor (URD; N = 71), 1-antigen mismatched URD (N = 26), or 1-antigen mismatched related donor (N = 3) using either total body irradiation (TBI)-based conditioning (N = 29) or non-TBI-based conditioning (N = 71). Compared to historical controls, the increase in posttransplantation day +7 TNFR1 ratios was not altered in patients who received TBI-based conditioning, but was 40% lower in patients receiving non-TBI-based conditioning. The latter group experienced relatively low rates of severe grade 3 to 4 GVHD (14%), 1-year NRM (16%), and high 1-year survival (69%). These findings suggest that (1) the effectiveness of TNF-inhibition with etanercept may depend on the conditioning regimen, and (2) attenuating the expected rise in TNFR1 levels early posttransplantation correlates with good outcomes.

KW - GVHD

KW - Hematopoietic cell transplantation

KW - TNF-α

KW - TNFR1

UR - http://www.scopus.com/inward/record.url?scp=84866144232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866144232&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.03.013

DO - 10.1016/j.bbmt.2012.03.013

M3 - Article

C2 - 22469883

AN - SCOPUS:84866144232

VL - 18

SP - 1525

EP - 1532

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -